12 research outputs found
Milrinone and Mortality in Adult Cardiac Surgery: A Meta-analysis
Objective: The authors conducted a review of randomized
studies to show whether there are any increases or decreases
in survival when using milrinone in patients undergoing
cardiac surgery.
Design: A meta-analysis.
Setting: Hospitals.
Participants: Five hundred eighteen patients from 13 randomized
trials.
Interventions: None.
Measurements and Main Results: BioMedCentral, PubMed
EMBASE, the Cochrane central register of clinical trials, and
conference proceedings were searched for randomized trials
that compared milrinone versus placebo or any other control
in the setting of cardiac surgery that reported data on
mortality. Overall analysis showed that milrinone increased
perioperative mortality (13/249 [5.2%] in the milrinone
group v 6/269 [2.2%] in the control arm, odds ratio [OR]
2.67 [1.05-6.79], p for effect 0.04, p for heterogeneity
0.23, I2 25% with 518 patients and 13 studies included).
Subanalyses confirmed increased mortality with milrinone
(9/84 deaths [10.7%] v 3/105 deaths [2.9%] with other drugs
as control, OR 4.19 [1.27-13.84], p 0.02) with 189 patients
and 5 studies included) but did not confirm a difference
in mortality (4/165 [2.4%] in the milrinone group v
3/164 [1.8%] with placebo or nothing as control, OR 1.27
[0.28-5.84], p 0.76 with 329 patients and 8 studies included).
Conclusions: This analysis suggests that milrinone might
increase mortality in adult patients undergoing cardiac surgery.
The effect was seen only in patients having an active
inotropic drug for comparison and not in the placebo subgroup.
Therefore, the question remains whether milrinone
increased mortality or if the control inotropic drugs were
more protective
Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity
This study was designed to evaluate contrast-enhanced ultrasound imaging of carotid atherosclerosis as a clinical tool to study intraplaque neovascularization
Blood damage in Left Ventricular Assist Devices: Pump thrombosis or system thrombosis?
Introduction: Despite significant technical advancements in the design and manufacture of Left Ventricular Assist Devices, post-implant thrombotic and thromboembolic complications continue to affect long-term outcomes. Previous efforts, aimed at optimizing pump design as a means of reducing supraphysiologic shear stresses generated within the pump and associated prothrombotic shear-mediated platelet injury, have only partially altered the device hemocompatibility. Methods: We examined hemodynamic mechanisms that synergize with hypershear within the pump to contribute to the thrombogenic potential of the overall Left Ventricular Assist Device system. Results: Numerical simulations of blood flow in differing regions of the Left Ventricular Assist Device system, that is the diseased native left ventricle, the pump inflow cannula, the impeller, the outflow graft and the anastomosed downstream aorta, reveal that prothrombotic hemodynamic conditions might occur at these specific sites. Furthermore, we show that beyond hypershear, additional hemodynamic abnormalities exist within the pump, which may elicit platelet activation, such as recirculation zones and stagnant platelet trajectories. We also provide evidences that particular Left Ventricular Assist Device implantation configurations and specific post-implant patient management strategies, such as those allowing aortic valve opening, are more hemodynamically favorable and reduce the thrombotic risk. Conclusion: We extend the perspective of pump thrombosis secondary to the supraphysiologic shear stress environment of the pump to one of Left Ventricular Assist Device system thrombosis, raising the importance of comprehensive characterization of the different prothrombotic risk factors of the total system as the target to achieve enhanced hemocompatibility and improved clinical outcomes
Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial
Management of acute decompensated heart failure patients presenting with cardiogenic shock (CS) is not straightforward, as few data are available from clinical trials. Stabilization before left ventricle assist device (LVAD) or heart transplantation (HTx) is strongly advocated, as patients undergoing LVAD implant or HTx in critical status have worse outcomes. This was a multicenter phase II study with a Simon 2-stage design, including 24 consecutive patients treated with low-moderate epinephrine doses, whose refractory CS prompted implantation of intra-aortic balloon pump (IABP) which was subsequently upgraded with peripheral venoarterial extracorporeal membrane oxygenation. At admission, patients had severe left ventricular dysfunction and overt CS, 7 patients could be managed only with inotropic therapy, and 16 patients were transitioned to IABP and 1 to IABP and venoarterial extracorporeal membrane oxygenation; the median duration of epinephrine therapy was 7\u202fdays (interquartile range 6-15), and the median dose was 0.08 \u3bcg/kg/min (interquartile range 0.05-0.1); 21 patients (87.5%) survived at 60\u202fdays (primary outcome); among them, 13 (61.9%) underwent LVAD implantation, 2 (9.5%) underwent HTx, and 6 (28.6%) improved on medical treatment, indicating that early and intensive treatment of CS in chronic advanced heart failure patients with low-dose epinephrine and timely short-term mechanical circulatory support leads to satisfactory outcomes